Evidence map›Paper›PMID 32824744›Full record

ReviewInternational journal of molecular sciences2020

Necroptosis in Hepatosteatotic Ischaemia-Reperfusion Injury.

Raji Baidya, Darrell H G Crawford, Jérémie Gautheron, Haolu Wang, Kim R Bridle

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
4.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. New Frontiers in Organ Preservation and Hepatoprotection.International journal of molecular sciences · 2022
    Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Raji BaidyaFaculty of Medicine, The University of Queensland, Brisbane, Queensland QLD 4006, Australia.
Darrell H G CrawfordFaculty of Medicine, The University of Queensland, Brisbane, Queensland QLD 4006, Australia.
Jérémie GautheronSorbonne University, Inserm, Centre de Recherche Saint-Antoine (CRSA), 75012 Paris, France.
Haolu WangGallipoli Medical Research Institute, Brisbane, Queensland QLD 4120, Australia.
Kim R BridleFaculty of Medicine, The University of Queensland, Brisbane, Queensland QLD 4006, Australia.
The University of Queensland · AUInserm · FR

Funding

Gallipoli Medical Research Foundation 2020
6 · The paper itself

Abstract

While liver transplantation remains the sole treatment option for patients with end-stage liver disease, there are numerous limitations to liver transplantation including the scarcity of donor livers and a rise in livers that are unsuitable to transplant such as those with excess steatosis. Fatty livers are susceptible to ischaemia-reperfusion (IR) injury during transplantation and IR injury results in primary graft non-function, graft failure and mortality. Recent studies have described new cell death pathways which differ from the traditional apoptotic pathway. Necroptosis, a regulated form of cell death, has been associated with hepatic IR injury. Receptor-interacting protein kinase 3 (RIPK3) and mixed-lineage kinase domain-like pseudokinase (MLKL) are thought to be instrumental in the execution of necroptosis. The study of hepatic necroptosis and potential therapeutic approaches to attenuate IR injury will be a key factor in improving our knowledge regarding liver transplantation with fatty donor livers. In this review, we focus on the effect of hepatic steatosis during liver transplantation as well as molecular mechanisms of necroptosis and its involvement during liver IR injury. We also discuss the immune responses triggered during necroptosis and examine the utility of necroptosis inhibitors as potential therapeutic approaches to alleviate IR injury.

Indexed as

NecroptosisAnimalsHumansLiverLiver TransplantationNon-alcoholic Fatty Liver DiseasePrimary Graft DysfunctionTissue and Organ Harvestingischaemia-reperfusion injuryliver transplantationnecroptosisnon-alcoholic fatty liver diseasesteatosis

Identifiers

PMID32824744
PMCPMC7460692
OpenAlexW3068768489

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.